# Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

> **NCT03447314** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 54 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** GSK1795091
- **DRUG:** GSK3174998
- **DRUG:** GSK3359609
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03447314
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-26
- **Primary completion:** 2020-07-01
- **Final completion:** 2022-03-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447314, "Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03447314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*